Cargando…

The journey of antimalarial drugs against SARS-CoV-2: Review article

The recent outbreak of coronavirus pandemic (COVID-19) introduced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has greatly affected the global public health. This pandemic disease became particularly threatening after the start of a new wave. Vaccines of tested efficacy to stop CO...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarhan, Amany A., Ashour, Nada A., Al‐Karmalawy, Ahmed A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132553/
https://www.ncbi.nlm.nih.gov/pubmed/34028468
http://dx.doi.org/10.1016/j.imu.2021.100604
_version_ 1783694935687430144
author Sarhan, Amany A.
Ashour, Nada A.
Al‐Karmalawy, Ahmed A.
author_facet Sarhan, Amany A.
Ashour, Nada A.
Al‐Karmalawy, Ahmed A.
author_sort Sarhan, Amany A.
collection PubMed
description The recent outbreak of coronavirus pandemic (COVID-19) introduced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has greatly affected the global public health. This pandemic disease became particularly threatening after the start of a new wave. Vaccines of tested efficacy to stop COVID-19 infection are being investigated vigorously worldwide. Currently, some specific drugs have been authorized for COVID-19, but the improvement of antivirals requires time. Hence, a faster way of treatment is done by drug repurposing. Repurposing of drugs is promising for treating and reducing the symptoms of the disease, and it a fast, easy, and safe method to address the crisis, because of their previously known applications. Some antimalarial drugs, especially chloroquine and hydroxychloroquine, have been repurposed, as they exhibited promising results in vitro and in vivo. This article investigates repurposed antimalarial drugs, focusing on their antiviral mechanisms of action, effects in combinations, trial results, and their side effects.
format Online
Article
Text
id pubmed-8132553
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher The Authors. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-81325532021-05-19 The journey of antimalarial drugs against SARS-CoV-2: Review article Sarhan, Amany A. Ashour, Nada A. Al‐Karmalawy, Ahmed A. Inform Med Unlocked Article The recent outbreak of coronavirus pandemic (COVID-19) introduced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has greatly affected the global public health. This pandemic disease became particularly threatening after the start of a new wave. Vaccines of tested efficacy to stop COVID-19 infection are being investigated vigorously worldwide. Currently, some specific drugs have been authorized for COVID-19, but the improvement of antivirals requires time. Hence, a faster way of treatment is done by drug repurposing. Repurposing of drugs is promising for treating and reducing the symptoms of the disease, and it a fast, easy, and safe method to address the crisis, because of their previously known applications. Some antimalarial drugs, especially chloroquine and hydroxychloroquine, have been repurposed, as they exhibited promising results in vitro and in vivo. This article investigates repurposed antimalarial drugs, focusing on their antiviral mechanisms of action, effects in combinations, trial results, and their side effects. The Authors. Published by Elsevier Ltd. 2021 2021-05-19 /pmc/articles/PMC8132553/ /pubmed/34028468 http://dx.doi.org/10.1016/j.imu.2021.100604 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Sarhan, Amany A.
Ashour, Nada A.
Al‐Karmalawy, Ahmed A.
The journey of antimalarial drugs against SARS-CoV-2: Review article
title The journey of antimalarial drugs against SARS-CoV-2: Review article
title_full The journey of antimalarial drugs against SARS-CoV-2: Review article
title_fullStr The journey of antimalarial drugs against SARS-CoV-2: Review article
title_full_unstemmed The journey of antimalarial drugs against SARS-CoV-2: Review article
title_short The journey of antimalarial drugs against SARS-CoV-2: Review article
title_sort journey of antimalarial drugs against sars-cov-2: review article
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8132553/
https://www.ncbi.nlm.nih.gov/pubmed/34028468
http://dx.doi.org/10.1016/j.imu.2021.100604
work_keys_str_mv AT sarhanamanya thejourneyofantimalarialdrugsagainstsarscov2reviewarticle
AT ashournadaa thejourneyofantimalarialdrugsagainstsarscov2reviewarticle
AT alkarmalawyahmeda thejourneyofantimalarialdrugsagainstsarscov2reviewarticle
AT sarhanamanya journeyofantimalarialdrugsagainstsarscov2reviewarticle
AT ashournadaa journeyofantimalarialdrugsagainstsarscov2reviewarticle
AT alkarmalawyahmeda journeyofantimalarialdrugsagainstsarscov2reviewarticle